ARAMIS: Phase 3 trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer | Prof Karim Fizazi at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, discusses the ongoing phase 3 ARAMIS trial, which is evaluating the efficacy and safety of the novel androgen receptor inhibitor, ODM-201, in men with high-risk non-metastatic castration-resistant prostate cancer.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews